Dengue vaccine study
Tuesday, 02 September, 2008
Avantogen [ASX: ACU] investee Hawaii Biotech will receive clinical trial support from the US Walter Reed Army Institute of Research (WRAIR) for its dengue fever vaccine program.
WRAIR has considerable experience with dengue fever and an established track record in emerging infectious diseases.
The recombinant-DNA-based vaccine candidate will soon undertake the clinical trial process.
Incidents of dengue, a close relative of the West Nile virus, are now growing rapidly in Australia and the Asian region.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
